Cambrian Bioworks LLP

Based in India, Cambrian Bioworks LLP develops advanced genomic technologies to improve patient care in diagnostics for cancer, infectious diseases, genetic conditions, and reproductive health. Cambrian Bioworks LLP, headquartered in Bangalore, India, was founded in 2020. The company focuses on advanced genomic technologies. The founder team includes Akshatha Ravi, Raghav Sridhar, and Vaibhav Hegde, who also serves as the CEO.

Cambrian Bioworks has completed one funding round, raising a total of USD 1. 45 mn in Seed funding on August 28, 2024. Cambrian Bioworks specializes in advanced genomic technologies, offering a suite of products designed to enhance the efficiency and effectiveness of patient care in the fields of cancer diagnostics, infectious disease testing, genetic disease screening, and reproductive health. Their core offerings include Manta, a robust platform for DNA/RNA extraction tailored for clinical and research applications, and Beluga, an automated sample-to-result system that seamlessly integrates nucleic acid extraction, quantification, and amplification.

These products cater to a diverse client base, including healthcare institutions, academic research facilities, and diagnostics laboratories primarily in North America, Europe, and select markets in Asia. The solutions are engineered to meet the needs of both small research teams and high-throughput facilities, enabling rapid processing of samples and yielding reliable genomic data essential for advanced medical diagnostics. Cambrian Bioworks generates revenue through direct sales of its flagship products, Manta and Beluga, leveraging a business-to-business (B2B) model that targets laboratories and healthcare facilities. Their transaction structure includes direct purchases, often facilitated through partnerships and collaborations with diagnostic firms and research institutions.

Each product is priced according to its capabilities and the specific needs of the clients, enabling tailored solutions for various genomic applications. The company also provides access to ancillary services such as product training and technical support, which further enhance customer engagement and foster long-term relationships. Through these transactional interactions, Cambrian Bioworks aims to establish a sustainable revenue model while expanding its footprint in the growing genomic diagnostics market. In August 2024, Cambrian Bioworks LLP raised USD 1.

45 mn in Seed funding led by the Irani family office, with participation from an individual investor. The funding will support the upcoming launch of new products and technologies aimed at enhancing genomic diagnostics. Cambrian plans to expand its reach into new markets, specifically targeting additional regions in Europe and Asia by the end of 2025.